Previous 10 | Next 10 |
2024-02-15 17:55:08 ET Summary VRNA's ensifentrine could be approved for the maintenance treatment of chronic obstructive pulmonary disease in June 2024. VRNA had $257M in cash at the end of Q3'23, and a debt facility worth up to $400M was set up in early 2024. While VRNA has ...
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 20...
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a wealth of strategic and operational experience in the bio...
2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...
2024-01-23 03:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-19 17:30:12 ET Summary Verona Pharma plc develops respiratory disease medicines, with its lead asset being ensifentrine, an inhaled dual inhibitor of PDE3 and PDE4 enzymes. Ensifentrine is being developed in multiple formulations and is currently under FDA review for the t...
2024-01-13 12:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan...
2024-01-02 04:56:29 ET More on Verona Pharma Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript Verona Pharma GAAP EPS of -$0.02 beats by $0.14 Seeking Alpha’s ...
News, Short Squeeze, Breakout and More Instantly...
Verona Pharma plc Company Name:
VRNA Stock Symbol:
NASDAQ Market:
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities Cash runway extended beyo...
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024...
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...